The emergence of coronavirus disease 2019 (COVID-19) in 2019 has rapidly become a global health emergency. COVID-19 develops from a severe acute respiratory syndrome coronavirus (SARS-CoV) infection, which directly impacts the cardiovascular system by disrupting angiotensin-converting enzyme-2 receptors in the tissues. This leads to severe complications that cause major morbidity and mortality. Several cardiovascular complications have been reported during the pandemic, including myocardial infarction, stroke, pulmonary embolism, myocarditis, and tachyarrhythmias. Although bradyarrhythmia is another cardiac event associated with COVID-19, it has been reported in only a few cases in the medical literature. Here, we report two cases of young adult patients who were admitted because of a positive reverse transcriptase-polymerase chain reaction test of SARS-CoV-2 and presented with bradycardia detected on electrocardiogram but had an otherwise normal health condition with no history of cardiovascular illness.

No abstract

Cerebral palsy (CP) is primarily a disease of movement and posture. Spastic CP is the most common type of CP and is characterized by muscle spasticity. The management of CP aims to improve the function of the patients. Botulinum toxin type A (BTX-A) is one of the most effective therapies for focal spasticity for children with CP. Rehabilitation is also effective for CP when applied to children aged younger than 6 years. The study aimed to assess the effect of the combination of a rehabilitation program and BTX-A on spastic CP among children by reviewing the previous studies conducted on this subject. PubMed and Google Scholar databases were used for searching purposes to obtain articles related to the subjects of interest. The included searching terms were rehabilitation, physiotherapy, CP, children, spasticity, effect, combination, and BTX-A, which were used in several combinations to obtain all possible articles related to the current subject. A total of 340 articles were obtained; only six articles were eligible for the inclusion criteria. The six studies included 368 patients, and the longest duration of assessment was up to 13 months. The collected data from the included studies were summarized in one table. The combination of BTX-A therapy and rehabilitation for spastic CP children resulted in significant improvements in function, reduction in spasticity, improving strength compared to using BTX-A alone.